Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Tech Today.
Press releases published on May 15, 2025
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
GlobeNewswire
·
May 15, 2025
In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial …
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 15, 2025
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic …
Christophe Girardier, CEO of Glimpact, to Speak at Three Public Events During hub.brussels’ Impact Mission 2025 in New York
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Christophe Girardier, CEO of Glimpact the first platform for analyzing the overall systemic environmental impact of products and organizations, will speak at three public events hosted by hub.brussels during …
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025 OPGx-BEST1 on …
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
GlobeNewswire
·
May 15, 2025
Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the …
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
GlobeNewswire
·
May 15, 2025
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May …
Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
—Reported Positive 48-Week Data from SPRING Trial—Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis— —Aligned with FDA on Pathway to …
Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 15, 2025
Obtained written alignment from the FDA on key elements of TSHA-102 pivotal Part B trial design and next steps on enabling study initiation The FDA advised the Company to submit pivotal Part B trial protocol and associated statistical analysis plan as an …
Polpharma Group plaide en faveur d’une action urgente en vue de garantir aux patients européens un accès équitable et précoce aux médicaments
GlobeNewswire
·
May 15, 2025
VARSOVIE, Pologne, 15 mai 2025 (GLOBE NEWSWIRE) -- Polpharma Group, acteur pharmaceutique de première importance, enjoint l’Union européenne à arrêter des mesures décisives pour finaliser la réforme du secteur pharmaceutique et renforcer la capacité du …
Polpharma Group fordert dringende Maßnahmen zum Schutz eines frühzeitigen und gerechten Zugangs zu Medikamenten für europäische Patienten
GlobeNewswire
·
May 15, 2025
WARSCHAU, Polen, May 15, 2025 (GLOBE NEWSWIRE) -- Die Polpharma Group, ein führendes Pharmaunternehmen, fordert die Europäische Union nachdrücklich auf, entschlossene Maßnahmen zu ergreifen, um die Arzneimittelreform abzuschließen und die Kapazitäten …
Launch a stable income contract through the BlockchainCloudMining platform to quickly realize the diversification of cryptocurrency assets and double the wealth
GlobeNewswire
·
May 15, 2025
Miami, FL, May 15, 2025 (GLOBE NEWSWIRE) -- In 2025, the cryptocurrency market is experiencing rapid development. With the steady rise in the price of Bitcoin (BTC) and the continuous innovation of major digital currencies such as Ethereum (ETH), investor …
Skyharbour and JV Partner Orano to Commence Extensive Summer 2025 Drilling Program at Preston Uranium Project
GlobeNewswire
·
May 15, 2025
Vancouver, BC, May 15, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”), is pleased to announce that its joint-venture partner, Orano Canada Inc. (“Orano”), will commence a …
ZenaTech Reports Nearly Double Revenue Year-Over-Year for the First Quarter of 2025
GlobeNewswire
·
May 15, 2025
VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum …
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
May 15, 2025
- Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic …
Avicanna Reports Q1 2025 Results and First Profitable Quarter
GlobeNewswire
·
May 15, 2025
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 15, 2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter …
SINTX Technologies Provides Business Update Highlighting Strategic Focus to Medical Device Commercialization
GlobeNewswire
·
May 15, 2025
Salt Lake City, UT , May 15, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), an advanced ceramics company pioneering medical and antipathogenic applications of silicon nitride (Si₃N₄), today provided a comprehensive update on its …
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 15, 2025
PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force PEMGARDA revenue re-acceleration observed in Q2 2025 to date Invivyd continues to …
Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 15, 2025
Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate doses Encouraging …
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
GlobeNewswire
·
May 15, 2025
LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating …